title: Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Banks
authors.forename: Eric
authors.initials: E
authors.lastname: Gerstenberger
authors.forename: Peter Q
authors.initials: PQ
authors.lastname: Eichacker
authors.forename: Charles
authors.initials: C
authors.lastname: Natanson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D008875:Middle Aged; D011486:Protein C / Q000191:economics* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D014481:United States
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated